MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.82
-0.24
-3.40%
Closed 19:59 07/29 EDT
OPEN
7.08
PREV CLOSE
7.06
HIGH
7.11
LOW
6.82
VOLUME
7.38M
TURNOVER
--
52 WEEK HIGH
18.77
52 WEEK LOW
0.2501
MARKET CAP
1.35B
P/E (TTM)
-20.8181
1D
5D
1M
3M
1Y
5Y
Is Ocugen Worth a Shot Because of the Worsening Pandemic?
Investor Place · 22h ago
Ocugen Stock Gets a New Street-High Price Target
Talks of a post-pandemic world can probably be put on hold for now. Turns out that with the emergence of mutant strains and, in particular, the fast-spreading Delta variant, Covid-19 is still very much an on-going concern. This is obviously bad news for al...
TipRanks · 3d ago
Ocugen, Inc.'s (NASDAQ:OCGN) Profit Outlook
We feel now is a pretty good time to analyse Ocugen, Inc.'s ( NASDAQ:OCGN ) business as it appears the company may be...
Simply Wall St. · 3d ago
Biden officials contemplate the need of COVID-19 booster shots in vulnerable Americans
LarisaBozhikova/iStock via Getty Images Amid ongoing discussions regarding the necessity of booster shots for prevention of COVID-19, Biden administration health officials believe that vulnerable populations will need booster shots, The
Seekingalpha · 3d ago
Pfizer/BioNTech COVID-19 shot is 39% effective with prevalence of Delta variant, Israel says
Scott Olson/Getty Images News With the spread of the highly transmissible Delta variant of the coronavirus, the effectiveness of the COVID-19 vaccine from Pfizer ([[PFE]] +0.6%)/BioNTech ([[BNTX]] +0.5%) has dropped
Seekingalpha · 6d ago
Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today
Investor Place · 07/20 16:16
54 Biggest Movers From Yesterday
Gainers
Benzinga · 07/20 09:05
Hot Stock: COVID vaccine stocks rally; AN rises on earnings; CALM falls; CYTK jumps on clinical data
Maximusnd/iStock via Getty Images The major averages tanked on Monday, with a sell-off in part driven by rising fears of a COVID resurgence. However, in the midst of the broad
Seekingalpha · 07/19 21:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCGN. Analyze the recent business situations of Ocugen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCGN stock price target is 7.30 with a high estimate of 15.00 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 30.24M
% Owned: 15.26%
Shares Outstanding: 198.23M
TypeInstitutionsShares
Increased
15
8.62M
New
49
3.60M
Decreased
11
1.52M
Sold Out
13
687.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Chief Executive Officer/Director
Shankar Musunuri
Chief Financial Officer/Secretary
Sanjay Subramanian
Senior Vice President
Vijay Tammara
Independent Director
Kirsten Castillo
Independent Director
Prabhavathi Fernandes
Independent Director
Uday Kompella
Independent Director
Ramesh Kumar
Independent Director
Manish Potti
Independent Director
Suha Taspolatoglu
Independent Director
Junge Zhang
No Data
About OCGN
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.